Pall Corporation

Case Study:
ABL Scales Up
Lentiviral
Production

Reduce Development Risk and Increase Your Speed to Market with iCELLis® Bioreactor Systems


The iCELLis bioreactor system, a well-established technology accepted by regulatory agencies for viral vector production of adherent cells, is used in the commercial manufacturing of Zolgensma an AAV-based viral vector gene therapy. The process was approved by the Food and Drug Administration in 2019.

Watch the 15-minute video or download the poster to learn how Advanced Bioscience Laboratories Inc. (ABL) scaled up a lentiviral production process from the iCELLis Nano bioreactor to the iCELLis 500+ bioreactor.


The video and poster address:
  • The challenges of lentivirus production.
  • The advantages of the iCELLis fixed bed bioreactor, an automated, single-use, fixed-bed bioreactor that provides excellent conditions for viral vector production in adherent cells.
  • Proven comparable performance of the iCELLis Nano bioreactor and the iCELLis 500+ bioreactor.

Watch video and download the poster today!

Fill out the form to watch video and download poster

*Indicates required fields